Wall Street Zen cut shares of Obsidian Therapeutics (NASDAQ:OBX – Free Report) from a hold rating to a sell rating in a research report sent to investors on Saturday morning,Wall Street Zen reports.
A number of other research analysts have also recently commented on the company. Piper Sandler initiated coverage on Obsidian Therapeutics in a research note on Wednesday, August 5th. They issued an “overweight” rating and a $42.00 price target for the company. TD Cowen initiated coverage on Obsidian Therapeutics in a report on Thursday, August 6th. They set a “buy” rating on the stock. Weiss Ratings started coverage on Obsidian Therapeutics in a report on Wednesday, September 2nd. They set a “sell (d-)” rating on the stock. Lifesci Capital began coverage on Obsidian Therapeutics in a research report on Tuesday, August 18th. They set an “outperform” rating and a $43.00 price objective on the stock. Finally, William Blair upgraded Obsidian Therapeutics to a “strong-buy” rating in a research report on Wednesday, September 23rd. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $39.00.
Read Our Latest Research Report on OBX
Obsidian Therapeutics Trading Down 3.5%
NASDAQ OBX opened at $11.77 on Friday. The business’s fifty day moving average is $17.05. Obsidian Therapeutics has a fifty-two week low of $11.61 and a fifty-two week high of $49.97.
About Obsidian Therapeutics
Obsidian Therapeutics is a biotechnology company focused on developing engineered cell and gene therapies for serious diseases. Its research centers on technologies designed to control the activity, timing and location of therapeutic proteins within engineered cells.
The company’s CytoDRiVE platform is intended to enable small-molecule regulation of protein expression, which may help improve the safety and effectiveness of cell therapies. Obsidian has applied this technology to immune-cell therapies, including programs designed to support the treatment of solid tumors, as well as to other therapeutic protein and gene-modulation applications.
Obsidian Therapeutics is based in the United States and has operated as a privately held biotechnology company, according to available company information.
See Also
- Five stocks we like better than Obsidian Therapeutics
- Rocket Lab’s Neutron Delay Leaves Wall Street Bullish But Raises the Stakes for 2027
- ManpowerGroup Stock Sinks on Q3 Results, But Fundamentals Stay Solid
- Does the AI Selloff Put Alphabet’s Breakout in Doubt?
- Bank Earnings Are Mixed—These 2 ETFs Offer Very Different Paths to a Recovery
Receive News & Ratings for Obsidian Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Obsidian Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
